Weight loss drugs are more popular than ever, even in cycling, but do the health benefits some are seeing outweigh the risks ...
Novo Nordisk’s post-trial sell-off may be overdone. Click here for this comparative analysis of NVO and LLY stocks and see ...
Rubin said that sentiment reflects Main Street Economics organization’s core mission of helping Americans understand economic realities in plain language and encouraging policymakers to make difficult ...
Mumbai: Indian drugmaker Dr Reddy's Laboratories is likely to launch its generic semaglutide injection in the country in March under the brand name Obeda, according to two people familiar with ...
Patent protection for semaglutide expires in India in March 2026, triggering a rush among Indian drugmakers to prepare lower-cost versions ...
Indian drugmaker Dr Reddy's Laboratories is likely to launch its generic semaglutide injection in the country in March under ...
Patent protection for semaglutide, the active ingredient in Danish drugmaker Novo Nordisk's diabetes drug Ozempic and ...
Dr Reddy’s Laboratories is likely to launch its generic semaglutide injection in the country in March under the brand name ...
The country's anti-obesity market is headed for a pricing shake-up, with a clutch of pharma companies readying plans to launch affordable v.
Analysts say Novo Nordisk’s new obesity drug may be obsolete before it hits the shelves, underlining a massive fall from grace for the company behind the weight loss boom.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results